33 completed, 3 terminated, 3 unknown, 1 active not recruiting. 42 Phase 3, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 42 | Completed 33, Terminated 3, Unknown 3, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 12 | Completed 9, Unknown 2, Not yet recruiting 1 |
Follow Phobic Disorders: new trials by email Literature Review of Phobic Disorders trials Research Report on Phobic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Effectiveness of a Cardiac Coherence Exercise on MRI Success and Image Quality in Claustrophobic Patients cardiac coherence - Claustrophobia, MRI | Phase 2 / Phase 3 | Not yet recruiting | Fondation Ophtalmologique Adolphe de Rothschild | 220 | 2026-01-01 | 2025-12-30 |
| Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder VQW-765, Placebo - Social Anxiety Disorder (SAD) | Phase 3 | Active not recruiting | Vanda Pharmaceuticals | 500 | 2025-09-22 | 2026-08-17 |
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety Centanafadine, Placebo - ADHD, Anxiety | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 315 | 2025-03-26 | 2026-05-06 |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) Fasedienol Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder (SAD) | Phase 3 | Completed | VistaGen Therapeutics, Inc. | 238 | 2024-09-16 | 2026-11-04 |
| Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1 225 mg BNC210, Placebo - Social Anxiety Disorder | Phase 3 | Completed | Bionomics Limited | 370 | 2024-08-06 | 2026-05-19 |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) Fasedienol Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder | Phase 3 | Completed | VistaGen Therapeutics, Inc. | 238 | 2024-03-28 | 2026-11-03 |
| Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Cannabidiol (CBD) Oil Capsules, Sunflower Lecithin Oil in Capsule - Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Unknown | McMaster University | 50 | 2021-12-15 | 2023-02-14 |
| Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD) PH94B - Social Anxiety Disorder | Phase 3 | Terminated | VistaGen Therapeutics, Inc. | 481 | 2021-10-01 | 2025-10-21 |
| PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2 PH94B Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder | Phase 3 | Terminated | VistaGen Therapeutics, Inc. | 228 | 2021-08-30 | 2025-11-24 |
| PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge PH94B Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder | Phase 3 | Completed | VistaGen Therapeutics, Inc. | 224 | 2021-05-24 | 2025-09-12 |
| Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose), Placebo Oil - Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Withdrawn | McMaster University | 2021-04-01 | 2021-03-24 | |
| Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder BHV-0223, Placebo - Social Anxiety Disorder, Performance Anxiety | Phase 2 / Phase 3 | Completed | Yale University | 22 | 2017-01-01 | 2021-05-20 |
| Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) PH94B, Placebo - Social Anxiety Disorder | Phase 3 | Completed | Pherin Pharmaceuticals, Inc. | 23 | 2014-03-01 | 2015-12-07 |
| Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Virtual Reality Exposure Therapy (VRET) - Phobic Disorders | Phase 2 / Phase 3 | Completed | VU University of Amsterdam | 56 | 2013-03-01 | 2015-07-08 |
| Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Computerized Cognitive Behavioral Therapy, Treatment as usual - Generalized Anxiety Disorder, Social Phobia | Phase 3 | Completed | University of South Florida | 100 | 2011-08-01 | 2019-06-18 |
| Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice CBT-Manualized Intervention, CBT-Treatment as Usual - Social Phobia | Phase 2 / Phase 3 | Unknown | Technische Universität Dresden | 116 | 2010-09-01 | 2011-07-08 |
| Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Cognitive-behavioral therapy, Treatment as Usual - Autism, Asperger's Syndrome | Phase 2 / Phase 3 | Completed | University of South Florida | 45 | 2010-04-01 | 2013-04-02 |
| D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia Individual Cognitive Behavioral Therapy (CBT), D-Cycloserine, Placebo - Phobic Disorders | Phase 3 | Completed | Southern Methodist University | 40 | 2010-04-01 | 2013-02-21 |
| Mechanisms of Panic Disorders Treatment Cognitive Behavioural Therapy (CBT) - Panic Disorder, Agoraphobia | Phase 2 / Phase 3 | Unknown | University Medicine Greifswald | 180 | 2010-03-01 | 2011-04-11 |
| Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety Group Cognitive Behavioral Therapy, Yohimbine Hydrochloride, Sugar Pill - Social Anxiety Disorder | Phase 3 | Completed | Southern Methodist University | 40 | 2009-03-01 | 2013-11-11 |
Showing 20 of 42. Sign in to see all of them.
Phobia, Social (34) · Anxiety Disorders (18) · Generalized Anxiety Disorder (9) · Panic Disorder (6) · Agoraphobia (5) · Anxiety, Separation (4) · Psychological Well-Being (3) · Acrophobia (2) · Aerophobia (2) · Disease (2) · Marijuana Abuse (2) · Mental Disorders (2) · Obsessive-Compulsive Disorder (2) · Asperger Syndrome (1)
Mental Disorders (40) · Anxiety Disorders (24) · Neurodevelopmental Disorders (6) · Pathological Conditions, Signs and Symptoms (4) · Behavior (3) · Pathologic Processes (3) · Personal Satisfaction (3) · Chemically-Induced Disorders (2) · Substance-Related Disorders (2) · Attention Deficit and Disruptive Behavior Disorders (1) · Autism Spectrum Disorder (1) · Child Development Disorders, Pervasive (1) · Communication Disorders (1) · Disease Attributes (1)
Cognitive Behavioral Therapy (8) · Quetiapine Fumarate (3) · Sugars (3) · Cycloserine (2) · Paroxetine (2) · Therapeutics (2) · Virtual Reality Exposure Therapy (2) · Cannabidiol (1) · Capsules (1) · Counseling (1) · Duloxetine Hydrochloride (1) · Escitalopram (1) · Exercise (1) · Fluoxetine (1) · Fluvoxamine (1)
VistaGen Therapeutics, Inc. (5) · GlaxoSmithKline (2) · McMaster University (2) · Southern Methodist University (2) · University of South Florida (2) · VU University of Amsterdam (2) · AstraZeneca (1) · Bionomics Limited (1) · Boston University Charles River Campus (1) · Connor, Kathryn M., M.D. (1) · Duke University (1) · Fondation Ophtalmologique Adolphe de Rothschild (1) · Haukeland University Hospital (1) · Johns Hopkins University (1) · Karolinska Institutet (1)
United States (25) · Canada (3) · Netherlands (3) · Germany (2) · Japan (2) · Norway (2) · Puerto Rico (1) · Sweden (1)
Eric A Storch, Ph.D. (2) · Jasper Smits, Ph.D. (2) · Michael Van Ameringen, MD, FRCPC (2) · Alexander L. Gerlach, Prof. Dr. (1) · Alfons O. Hamm, Prof. Dr. (1) · Asle Hoffart, Dr Psychol (1) · Barbara Milrod, MD (1) · David H Barlow, PhD (1) · Finn-Magnus Borge, Cand Psychol (1) · Georg W. Alpers, Prof. Dr. (1) · Jaakko Lappalainen, MD, PhD (1) · Jack Gorman, MD (1) · Jacques P. Barber, PhD (1)
PMID 18030084, PMID 18974308, PMID 20013046, PMID 20051130, PMID 20206470, PMID 21391024, PMID 21483704, PMID 22122292, PMID 22320999, PMID 22647314, PMID 23098672, PMID 23332511, PMID 23357440, PMID 24129543, PMID 24237691, PMID 24260145, PMID 24417601, PMID 24477837, PMID 24565357, PMID 24610431, PMID 25461793, PMID 25721183, PMID 26081010, PMID 26366886, PMID 26663632, PMID 26708332, PMID 26877119, PMID 27235836, PMID 27464313, PMID 27561175, PMID 28735699, PMID 28956620, PMID 29336228, PMID 29877727, PMID 29960692, PMID 30256548, PMID 30341278, PMID 30718541, PMID 30773148, PMID 30821630, PMID 30869969, PMID 30906874, PMID 31471911, PMID 31712720, PMID 31734525, PMID 31838872, PMID 32105128, PMID 32584211, PMID 32734299, PMID 33705168
R01MH045963 (1), R01MH045964 (1), R01MH045965 (1), R01MH045966 (1), R01MH053703 (1), R01MH064481 (1), R01MH064726 (1), R01MH070664 (1), R01MH075889 (1), R01MH078308 (1), U01MH064089 (1)